IntelliHep Grow Laboratory Activities in MerseyBIO

2Bio is pleased to announce that IntelliHep Ltd. has expanded their activities within the MerseyBIO Incubator.

IntelliHep is exploiting novel technologies and expertise to deliver new heparin-based glycans as novel drug leads in specific disease applications. Their in-house research and development activities at MerseyBIO will enable the company to develop their novel candidate molecules as Alzheimer therapeutics, as well as supporting strategic collaborative alliances with external partners on other disease areas.

Heparin is a complex sugar which is well known for its widespread use as an anti-coagulant drug. Heparinbased glycans influence a hugh variety of cellular events associated with major disease groups and represent drug targets of increasing importance.

The IntelliHep team is made up of Dr Jack Elands, Chief Executive; Prof Jerry Turnbull, Chief Scientific Officer; Dr Ed Yates, Director of Chemistry; Dr Andy Powell, Director of Biology.

Commenting on IntelliHep’s expansion, Prof Jerry Turnbull, CSO said “We are delighted to take the next step in expanding our research and development activities by starting a lab in the MerseyBIO Incubator. With the
continued support of the 2Bio team, we anticipate a strong period of growth in the next phase of IntelliHeps’ development.”

Amy Wilkinson of 2Bio added “It is a great to see IntelliHep Ltd. developing so well. The company has seen steady, organic growth over the last few years, and this next phase of their evolution has been eagerly awaited by the MerseyBIO management team. We are looking to continuing our support to the IntelliHep team.

“This is a great example of the successful transfer and commercialisation of University-based research, and it is very encouraging to know that the MerseyBIO Incubator can play an important part in helping the University to achieve it’s strategic objectives in driving knowledge exchange and innovation”.

IntelliHep is actively seeking collaborative partnerships to advance the discovery and optimisation of their technology platforms.